Twist Bioscience Appoints Dennis Cho as Senior Vice President, General Counsel and Chief Ethics and Compliance Officer
September 27 2021 - 8:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the appointment of
Dennis Cho as senior vice president, general counsel and chief
ethics and compliance officer. Mr. Cho brings more than 25 years of
corporate legal experience, most of which has been in the biotech
industry.
“Dennis is a giant of biopharma deals with a proven track record
in, and commitment to, the biotech industry. He has provided
counsel on all types of transactions and collaborations, which
makes him ideal for the role at Twist,” commented Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We look
forward to having his guidance as Twist continues to grow and
expand.”
Mr. Cho was most recently assistant general counsel at CytomX
Therapeutics, where he was department head for all deals and
contracts as well as day-to-day lead on compliance and numerous
other legal subject matters. Prior to CytomX, Mr. Cho was the lead
transactional attorney on antibody-related licenses and
collaborations, major commercial agreements, and combination trials
at Seattle Genetics. Before that, he spent nine years at Celgene as
the lead West Coast attorney supervising over 100 business
transactions, including in- and out- licenses, options,
collaborations and M&A agreements, and held primary legal
responsibility for Celgene’s alliances, equity investments and “big
data” machine learning initiative. Prior to Celgene, Mr. Cho served
as general counsel for four private and public companies. He earned
his J.D. and a B.A. in Molecular Cell Biology (Genetics) from
University of California, Berkeley.
“I am thrilled to join the world class team at Twist. With four
distinct areas of growth in synthetic biology, NGS, biopharma and
data storage, the clear opportunity to really impact human progress
by improving health and sustainability is both incredibly exciting
and motivating,” said Mr. Cho.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210927005227/en/
For Twist Bioscience Angela Bitting SVP, Corporate
Affairs 925- 202-6211 media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Mar 2024 to Apr 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Apr 2023 to Apr 2024